- Live market news
- Stocks
- CADL
Candel Therapeutics, Inc.
CADLStockUnited States
Latest news on CADLranked by Oyticker for market impact
- 25Impact
CADL grants 85,900 stock options to 4 new employees at $10.44 exercise price
Candel Therapeutics issued inducement grants of stock options to new hires under Nasdaq Rule 5635(c)(4), a routine equity compensation mechanism for clinical-stage biotech.
CADLBiotechnologyPharmaceuticals - 62Impact
Candel reports sustained immune biomarkers >2 years post-aglatimagene in prostate cancer phase 3
Candel Therapeutics presented biomarker data from a completed phase 3 trial of aglatimagene besadenovec showing sustained immune remodeling beyond two years in localized intermediate- to high-risk prostate cancer patients at ASTRO 2026.
CADLBiotechnologyOncologyImmunotherapy
SEC filings
All its filingsWhat CADL filed
- 10 Sept 2026
Investor communication
- 9 Sept 2026
- 13 Aug 2026
- 13 Aug 2026
- 24 Jun 2026
- 16 Jun 2026
- 15 May 2026
- 14 May 2026
- 14 May 2026
From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.